Keratinocyte-derived TNF-a acts as an endogenous tumour promoter and can also regulate AP-1 activity in mouse epidermis. To gain further insight into TNF-a signalling during skin tumour formation, mice deficient in TNFR1 (TNFR1 À/À mice) or TNFR2 (TNFR2 À/À mice) were subjected to chemical carcinogenesis. Tumour multiplicity was significantly reduced in TNFR1 À/À and TNFR2 À/À mice compared to wild-type (wt) mice, suggesting that both receptors have protumour activity. However, TNFR1
Introduction
TNF-a is a key mediator of inflammation and the host response to injury, infection or neoplasia (Locksley et al., 2001 ). TNF-a elicits its pleiotropic cellular effects through binding two cell surface receptors that activate multiple signal transduction pathways (reviewed by MacEwan, 2002) . TNFR1 (p55 kDa TNFR) and TNFR2 (p75 kDa TNFR) are encoded by distinct genes that display 30% homology at the amino-acid level in their extracellular, cysteine-rich, and ligand-binding regions (Kitakata et al., 2002) . The intracellular sequences of TNFR1 and TNFR2 are largely unrelated enabling the recruitment of different signalling complexes to each receptor. The extracellular domains of both TNF-a receptor subtypes can be cleaved, generating soluble receptors that are able to bind TNF-a with high affinity (Kohno et al., 1990; Higuchi and Aggarwal, 1992) . It is widely accepted that TNFR1 is ubiquitously expressed whereas TNFR2 expression appears to be primarily restricted to haematopoietic and endothelial cells. TNFR1 is thought to mediate a majority of the biological effects of TNF-a, but the function of TNFR2 is less well characterized. There is limited knowledge regarding the role of either TNFR1 or TNFR2 in skin pathologies. Expression of TNFR1 and TNFR2 has been observed on murine keratinocytes (Zhuang et al., 1999) . TNFR1 has been reported to play a role in reepithelialization during wound healing (Mori et al., 2002) and UVB-induced keratinocyte apoptosis (Zhuang et al., 1999) , but TNFR2 function in skin remains unknown.
Work in this laboratory has determined a role for TNF-a in epithelial malignancy using a mouse skin model of multistage carcinogenesis (i.e. initiation, promotion and progression) (Moore et al., 1999; Arnott et al., 2002; Scott et al., 2003) . Initiation involves the conversion of epidermal cells into latent neoplastic cells (Morris, 2000) . Promotion requires repeated exposure of skin to a tumour promoter (such as 12-O-tetradecanoylphorbol 13-acetate (TPA)), which ultimately results in the clonal expansion of initiated cells into papillomas (DiGiovanni, 1992) . During tumour progression papillomas convert to squamous cell carcinomas (SCC). This well-defined model system allows the study of the target cells, target genes and biological events associated with neoplasia (Frame et al., 1998) . TNF-a appears to mediate tumour development since mice deficient in TNF-a either genetically (TNF-a À/À ) or by treatment with a neutralizing anti-TNF-a antibody are resistant to the promotion phase of skin carcinogenesis (Moore et al., 1999; Scott et al., 2003) . The mechanism of TNF-a signalling during tumour promotion has been partially delineated, with PKCa and AP-1 playing important roles (Arnott et al., 2002) . However, little is known regarding the proximal targets of TNF-a signalling in this process.
In the present work, the putative involvement of TNFR1 and TNFR2 in skin tumour formation was investigated. We report that although TNFR1 plays a dominant role in skin tumour promotion, the presence of both TNFR1 and TNFR2 is necessary for optimal TNF-a signalling during tumour development.
Results
Genetic deletion of either TNFR1 or TNFR2 reduces the susceptibility of mice to skin carcinogenesis Papilloma development after 9,10-dimethyl-1,2-benzanthracene (DMBA)/TPA two-stage carcinogenesis was studied in wild-type (wt), TNFR1
À/À and TNFR2 À/À mice ( Figure 1 ). The average number of papillomas per mouse was recorded on a weekly basis (tumour multiplicity). Papillomas were first observed 8-9 weeks after the start of TPA treatment and tumour multiplicity peaked at 15 weeks in all three genotypes (Figure 1a) . A comparison of maximum tumour multiplicity in wt, TNFR1 À/À and TNFR2 À/À mice is shown in Figure 1b . Both TNFR1 À/À and TNFR2 À/À mice developed significantly less tumours than wt mice (Po0.0001 and P ¼ 0.0006, respectively). TNFR1 À/À mice were extremely resistant to skin tumour formation, with tumour multiplicity being very similar to that observed in TNFa À/À mice on a C57Bl/6J background (Scott et al., 2003) . In contrast, a substantial number of tumours developed in TNFR2 À/À mice, although the tumour multiplicity was E2Àfold lower in TNFR2 À/À than wt mice throughout tumour promotion. Malignant conversion of papillomas to SCC was not observed in wt, TNFR1
À/À and TNFR2 À/À mice during the 26 weeks of the experiment.
TNFR1 and TNFR2 are differentially expressed in wt epidermis during tumour promotion in vivo
To further understand the individual roles of the TNF-a receptor subtypes in skin tumour development we first examined the expression profile and distribution of TNFR1 and TNFR2 (mRNA and protein) in epidermis from wt mice. TNFR1 and TNFR2 mRNA and protein were detected in wt epidermis as measured by real-time RT-PCR and ELISA, respectively. TPA treatment did not markedly induce TNFR1 mRNA or protein expression in wt mice (Figure 2 and data not shown, respectively). In contrast, TNFR2 mRNA expression was upregulated at both 6 h (4.5-fold) and 24 h (3.3-fold) after TPA treatment of wt mice (Figure 2 ). Induction of TNFR2 protein expression in wt epidermis was also observed 6 h after TPA treatment (239 pg/mg compared with 169 pg/mg total protein in control). These data are in agreement with the literature, which suggests that expression of TNFR1 is stable and unaffected by cytokines and activating molecules whereas TNFR2 is inducible (Vandenabeele et al., 1995; MacEwan, 2002; and references therein) . It has been proposed that the biological response to TNF-a depends upon the ratio of TNFR1 : TNFR2 expression on the cell surface (MacEwan, 2002) . Analysis of wt epidermis revealed that despite induction of TNFR2 protein during tumour promotion, TNFR1 was the most prevalent TNF-a receptor subtype present in epidermis after TPA treatment (e.g. average expression of TNFR1 and TNFR2 after 6 h was 444 and 239 pg/mg total protein, respectively, giving a ratio of E2 : 1).
Genetic deletion of TNFR1 or TNFR2 does not affect expression of the remaining TNF-a receptor subtype
The levels of TNFR1 mRNA in TNFR2 À/À epidermis and TNFR2 mRNA in TNFR1 À/À epidermis were similar to TNFR1 and TNFR2 mRNA levels observed in wt epidermis as measured by real-time RT-PCR ( Figure 3a and b, respectively). This was confirmed at the protein level by measuring TNFR1 and TNFR2 expression by ELISA (data not shown). Collectively these data suggest that genetic deletion of one TNF-a receptor subtype is not compensated for by upregulation of the other subtype during tumour promotion.
Epidermal TNF-a expression is not affected by deletion of either TNFR1 or TNFR2 in vivo It has been reported that genetic deletion of either TNFR1 or TNFR2 results in elevated LPS-stimulated TNF-a levels in serum (E5-fold relative to wt mice; Peschon et al., 1998) . Therefore the induction of TNF-a by TPA in wt, TNFR1 À/À and TNFR2 À/À mice was studied. TPA induced the expression of TNF-a mRNA in wt epidermis 5.1-fold 6 h after treatment, but expression was returning to basal levels by 24 h (Figure 4a ). The profile of epidermal TNF-a protein expression in wt mice correlated with these data (Figure 4b ). TNF-a expression was not significantly different in TNFR1 À/À and TNFR2 À/À mice compared to wt mice at either the mRNA or protein level (Figure 4a and b). This indicates that basal and TPA-stimulated induction of TNF-a is not dependent on the coexpression of TNFR1 and TNFR2. and TNFR2 À/À epidermis, returning to near basal levels by 24 h ( Figure 5a , top panel; Figure 5b 2.3-and 1.5-fold, respectively). To further investigate c-Jun regulation, the phosphorylation status of Ser73 in c-Jun was examined. Phosphorylation of Ser73 by the c-Jun Nterminal kinases, p46/p54 JNK, is thought to be critical for c-Jun transcriptional activation (Vogt, 2001 ) and necessary for skin tumour development (Behrens et al., 2000) . Phospho-Ser73-c-Jun levels increased upon TPA treatment in all three genotypes ( Figure 5a TNFR1 and TNFR2 play discrete roles in the regulation of several TPA-responsive genes in vivo
The extent of transcriptional activation conferred upon AP-1-responsive genes is a function of the particular AP-1 heterodimers that are formed and the cell type in which they are expressed (Rutberg et al., 1996) . Since cJun was differentially regulated by TPA in TNFR1 À/À and TNFR2
À/À epidermis we sought to determine the requirement for TNFR1 and TNFR2 in the expression of several AP-1-responsive genes, namely granulocyte/ macrophage-colony stimulating factor (GM-CSF), matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase-3 (MMP-3). Deletion of TNFR1 or TNFR2 altered the expression of these AP-1-responsive genes to Figure 4 Epidermal TNF-a expression is not affected by deletion of either TNFR1 or TNFR2 in vivo. mRNA was extracted from wt, TNFR1 À/À and TNFR2 À/À epidermis at the times indicated after TPA treatment and subjected to real-time RT-PCR for TNF-a. Error bars represent mean7s.e. (n ¼ 3) (a). Epidermal protein homogenates were made at the times specified after TPA treatment. TNF-a protein levels were measured by ELISA. Results are expressed as picogram TNF-a per milligram total protein (mean7s.e., n ¼ 5) (b) Figure 5 c-Jun is differentially regulated in wt, TNFR1
À/À and TNFR2 À/À epidermis during tumour promotion in vivo. Nuclear protein homogenates were made at the times specified (h) after TPA treatment in wt, TNFR1
À/À and TNFR2 À/À epidermis. Data are representative of two independent experiments. Equal quantities of nuclear extract were subjected to Western blotting against an anti-c-Jun antibody (top panel), an antiphospho-Ser73-c-Jun antibody (middle panel) and an anti-b-actin antibody (lower panel) (a). Quantitation of TPA-stimulated c-Jun expression in wt, TNFR1 À/À and TNFR2 À/À epidermis relative to b-actin levels (mean7s.e., n ¼ 2) (b) differing extents during tumour promotion ( Figure 6 ). Epidermal MMP-9 protein expression was markedly reduced in TNFR1 À/À mice at 6 and 24 h after TPA treatment and in TNFR2 À/À mice at 24 h, when compared to wt mice (Figure 6a ). The effect on MMP-9 expression was more striking upon deletion of TNFR1 at both timepoints (Figure 6a ). In contrast, GM-CSF protein expression was significantly lower in TNFR2 À/À epidermis compared to wt 6 h after TPA treatment (Figure 6b ; P ¼ 0.029), whereas GM-CSF expression was only slightly reduced in TNFR1 À/À mice. MMP-3 mRNA induction was inhibited to similar extents in both TNFR1
À/À and TNFR2 À/À epidermis compared to wt, 6 h after TPA treatment (Figure 6c ; 5.2-and 6.8-fold compared to 13.9-fold, respectively). Taken together, these data indicate that TNFR1 and TNFR2 may regulate TNF-a signalling during skin carcinogenesis via multiple c-Jun containing AP-1 complexes, since deletion of TNFR1 or TNFR2 had distinct effects on the TPA-induced expression of AP-1-responsive genes.
TNFR1 and TNFR2 cooperate to mediate TNF-a effects in vitro
Several mechanisms have been suggested to explain the cooperation that occurs between TNFR1 and TNFR2 when a cell encounters a TNF-a stimulus. We show in this paper that both TNF-a receptor subtypes play a role in events leading to skin tumour development. To extend this observation, an in vitro model system was developed using primary keratinocytes (NBK) isolated from wt, TNFR1 À/À and TNFR2 À/À mice to study putative TNF-a receptor interplay in epidermis. Growth rates of NBK isolated from wt, TNFR1 À/À and TNFR2 À/À mice were similar over a period of 7 days (data not shown). NBK isolated from wt mice expressed both TNFR1 and TNFR2 mRNA (data not shown) and protein (average levels of transmembrane TNFR1 and TNFR2 were 52 and 14 pg/mg total protein, respectively). TNF-a receptor signalling on NBK was measured by stimulating cells with TNF-a, since TPA causes keratinocyte differentiation in vitro as opposed to keratinocyte proliferation in vivo. GM-CSF and MMP-9 were selected as biomarkers to measure TNF-a responsiveness of NBK isolated from wt, TNFR1 À/À and TNFR2 À/À mice. Treatment of wt NBK with TNF-ainduced MMP-9 protein expression (Figure 7a ). This TNF-a-mediated MMP-9 induction was abrogated in the absence of TNFR1 and markedly reduced in TNFR2 À/À NBK (Figure 7a) . Deletion of the TNF-a receptors had a similar effect on GM-CSF induction by Figure 6 TNFR1 and TNFR2 play discrete roles in the regulation of several TPA-responsive genes in vivo. Epidermal protein homogenates were made at the times specified (h) after TPA treatment of wt, TNFR1
À/À and TNFR2 À/À mice. Results are representative of at least two independent experiments. MMP-9 protein expression was analysed by zymography (a). GM-CSF protein levels were measured by ELISA. Results are expressed pg/ mg GM-CSF per mg total protein (mean7s.e., n ¼ 4; *P ¼ 0.029) (b). mRNA was extracted from wt, TNFR1
À/À and TNFR2 À/À epidermis at the times indicated after TPA treatment and subjected to real-time RT-PCR for MMP-3. Error bars represent mean7s.e. (n ¼ 3) (c) Figure 7 TNFR1 and TNFR2 cooperate to mediate TNF-a effects in vitro. NBK were isolated from wt, TNFR1 À/À and TNFR2 À/À mice and treated with TNF-a in vitro. Results are representative of at least two independent experiments. MMP-9 protein levels in cell culture supernatant were analysed by zymography after treatment with 10 ng/ml TNF-a for 24 h (a). GM-CSF protein expression in cell culture supernatant was measured by ELISA after treatment with increasing concentrations of TNF-a for 24 h. Results are expressed as pg/ml GM-CSF protein (mean7s.e., n45; *Po0.03) (b)
TNF-a receptors in tumour development CH Arnott et al TNF-a (Figure 7b ). TNF-a-induced GM-CSF expression in a dose-dependent manner in wt NBK and was maximal at 100 ng/ml TNF-a (3-fold compared to control; P ¼ 0.0012). GM-CSF was not induced by TNF-a in TNFR1 À/À NBK (Figure 7b ). Dose-dependent GM-CSF expression was observed upon treatment of TNFR2 À/À NBK with TNF-a although levels were significantly reduced compared to wt NBK (Figure 7b ; Po0.03). These data suggest that TNFR1 plays a dominant role in mediating TNF-a effects on keratinocytes and that TNFR2 alone is not sufficient to elicit a TNF-a response. However, an absence of TNFR2 reduces the threshold of TNFR1 signalling suggesting that both TNFR subtypes are required by keratinocytes for optimal TNF-a signalling.
Discussion
Carcinogenesis in humans and laboratory animals is a multistage process involving initiation, promotion and progression. Recently, a critical role for TNF-a has been established in skin tumour development (Moore et al., 1999; Suganuma et al., 1999; Scott et al., 2003) . Work described here furthers this observation by demonstrating that both TNFR1 and TNFR2 have protumour actions, but act via different mechanisms. Genetic deletion of TNFR1 or TNF-a rendered mice equally resistant to skin carcinogenesis (Scott et al., 2003) . Hence, the tumour multiplicity data suggest that TNFR1 plays a dominant role in eliciting the tumour promoting activity of TNF-a, whereas TNFR2 acts in an accessory fashion.
Distribution of TNFR1 and TNFR2 in skin and their relative contribution in TNF-a related skin pathologies is not well characterized. TNFR1 expression was comparatively higher than that of TNFR2 during tumour promotion possibly reflecting the importance of TNFR1 in the skin carcinogenesis model. Modulation of TNFR2 by numerous stimuli in other tissues has been reported (MacEwan, 2002) , suggesting that TNFR2 regulation is generally more flexible than TNFR1. We have shown for the first time that both TNFR1 and TNFR2 are constitutively expressed in epidermis and TNFR2 expression is upregulated after tumour promotor treatment in vivo. The TPA-stimulated change in TNFR2 levels coupled to largely unmodulated TNFR1 expression observed in epidermis may be important for TNF-a to mediate its tumour promoting effects.
It has been suggested that TNFR1 and TNFR2 can function independently (Medvedev et al., 1996 and references therein) or cooperatively (Tartaglia et al., 1993; Pinckard et al., 1997; Chan and Lenardo, 2000) to mediate TNF-a signalling. We show that TNF-a signals via both receptor subtypes in an independent manner in vivo, since several AP-1-responsive genes (GM-CSF, MMP-9 and MMP-3) were differentially expressed in the absence of either TNFR1 or TNFR2 during skin tumour promotion. c-Jun appeared to regulate TNFR1-and TNFR2-dependent expression of GM-CSF, MMP-9 and MMP-3, since a decrease in TPA-stimulated c-Jun expression and phosphorylation was concomitant with reduced expression of these AP-1-responsive genes. These data are supported by work demonstrating that c-Jun plays a key role in tumour development in vivo (Young et al., 1999; Zhong et al., 2001 ), TNF-a mediates the activation of AP-1 during skin tumour promotion (Arnott et al., 2002) and JNK (Mukhopadhyay et al., 2001; Littlejohn et al., 2003) and AP-1 transactivation (Yamada et al., 1997; Yamada and Fausto, 1998) can be mediated by either TNF-a receptor. Taken together, these data suggest a key role for AP-1 dependent signalling in TNFR1-and TNFR2-mediated tumour promotion. The role of other signalling pathways in TNFR1-and TNFR2-mediated papilloma development remains unclear at present and will be the focus of future investigation. A previous study from our laboratory investigated the regulation of a variety of AP-1-responsive and nonresponsive genes in wt and TNF-a À/À mice during tumour promotion (Arnott et al., 2002) . In agreement with the present study, a critical role for AP-1 signalling in TNF-a-mediated tumour promotion was demonstrated, since the subset of genes found to be differentially regulated in wt and TNF-a À/À mice were all AP-1 responsive (Arnott et al., 2002) .
Different AP-1 complexes have specific and nonoverlapping cellular functions in vivo (Szabowski et al., 2000) . The promoter elements of GM-CSF, MMP-9 and MMP-3 bind different AP-1 complexes in a selective manner (Szabowski et al., 2000; Hulboy et al., 2001; Papathoma et al., 2001 ). The present study shows that TNFR1 and TNFR2 can regulate multiple c-Jun containing AP-1 complexes, since differential expression of GM-CSF, MMP-9 and MMP-3 was observed in
. MMP-9, MMP-3 and GM-CSF have all been described as positive regulators of tumour development (Sternlicht et al., 1999; Coussens et al., 2000; Mann et al., 2001) . Thus, the induction of these genes may contribute to the protumour actions of TNFR1 and TNFR2.
In addition to independent signalling by TNFR1 and TNFR2, the TNF-a receptors have been proposed to act in a cooperative manner. Cooperation is thought to occur through either a 'ligand passing' mechanism (Tartaglia et al., 1993) or via amplification of intracellular signal transduction (Pinckard et al., 1997; Chan and Lenardo, 2000) . 'Ligand passing' is a consequence of TNF-a binding to TNFR2 with a greater affinity and half-life than to TNFR1 (Tartaglia et al., 1993) . Thus, TNFR2 concentrates TNF-a at the cell surface where it is subsequently passed to TNFR1 (Tartaglia et al., 1993) . Alternatively, TNFR1 and TNFR2 can cooperate at the intracellular level through crosstalk between the adaptor proteins they recruit (Pinckard et al., 1997; Chan and Lenardo, 2000) . Our in vitro model provides evidence for TNF-a receptor cooperation on keratinocytes, since TNFR2 was required for optimal TNFR1 signalling: although TNFR1 À/À cells did not respond to recombinant murine TNF-a, the induction of TNF-a biomarkers was reduced in TNFR2
À/À cells compared to wt. The transmembrane form of TNF-a is superior to soluble TNF-a in activating TNFR2 in some cell types (Grell et al., 1995) . This appeared to be the case in murine keratinocytes, making it difficult to fully elucidate the physiological role of TNFR2 in vitro. Thus, although we illustrated that TNFR2 is required for optimal TNFR1 signalling in vitro and in vivo, we were unable to determine the mechanism of TNFR1 and TNFR2 cooperation. Collectively, data presented in this study show for the first time that TNFR1 and TNFR2 play important roles in skin tumour formation. TNFR1-mediated signalling has recently been shown to enhance tumour formation during liver carcinogenesis (Knight et al., 2000) and upregulate the metastasis of colon carcinoma cells (Kitakata et al., 2002) . In contrast, a role for TNFR2 in malignancy has not previously been reported. In the present study, we have demonstrated that TNFR1 is critical for tumour development, but that coexpression of TNFR1 and TNFR2 is required for optimal TNF-a tumour promoting activity. In addition, we describe the novel observation that TNFR1 and TNFR2 signal via discrete AP-1 complexes to induce the expression of genes known to promote tumourigenesis. These data coupled with previously published work (Scott et al., 2003) provide further evidence to support the use of TNF-a antagonists in the treatment of some cancers. It is possible that TNF-a receptor usage is heterogeneous in a range of pathologies including malignancy, such that specific inhibition of each TNF-a receptor may be advantageous to anti-TNF-a therapies. Hence, the use of anti-TNF-a therapies, TNF-a receptor antagonists or procedures that modulate endogenous TNF-a receptor expression may have potential utility in cancer prevention and treatment.
Methods

Materials
Mice homozygous for the mutant TNFR1 or TNFR2 knockout allele on a C57Bl/6J background (TNFR1 À/À or TNFR2 À/À ) were purchased from Jackson Laboratories (Maine, USA). DMBA, TPA, the BCA protein assay kit and anti-b-actin antibody (Cat. No. 5441) were obtained from Sigma (Poole, UK). Real-time RT-PCR was performed using the ABI PRISM 7700 Sequence Detection System instrument and software (PE Applied Biosystems, Warrington, UK). Real-time analysis was performed using primers and probes that were either premade (TNF-a and 18 s rRNA) or designed using Primer Express 1.5a (TNFR1, TNFR2 and MMP-3) and subsequently purchased from PE Applied Biosytems. ELISAs for TNFR1, TNFR2, TNF-a and GM-CSF, proMMP-9 protein and recombinant murine TNF-a were from R&D systems (Oxon, UK). The anti-c-Jun (Cat. No. 9162) and antiphospho-Ser73-c-Jun (Cat. No. 9164) antibodies were purchased from New England Biolabs (MA, USA). Nitrocellulose (Hybond-ECL) and ECLt reagent were purchased from Amersham (UK). Type I collagen coated dishes were obtained from Becton Dickinson (Oxford, UK) and FAD media was purchased from JRH Biosciences (Andover, UK).
Skin carcinogenesis
Mice homozygous for the mutant TNFR1 or TNFR2 knockout allele (TNFR1 À/À or TNFR2
À/À
) and wt mice were maintained on a C57Bl/6J background. In each experiment, 6-week-old wt, TNFR1 À/À and TNFR2 À/À female mice were age matched to within 3 days. Shaved dorsal skin was initiated with DMBA (25 mg in 100 ml) and promoted with TPA (Moore et al., 1999) . TPA (4 mg in 100 ml acetone) was applied to the shaved area three times weekly for up to 15 weeks. Microchips were implanted dorsally and the average number of papillomas per mouse (tumour multiplicity) was recorded weekly for 26 weeks after the start of promotion. Papillomas were defined as raised lesions of at least 1 mm diameter that had been present for at least 2 weeks.
Measurement of mRNA by real-time RT-PCR
Mice were killed at the times indicated after one application of TPA or acetone (control). Dorsally shaved treated skin was removed and agitated in warm water (601C) for 5 s. Skin was spread on card and epidermis was scraped from the dermis using a spatula. Epidermis from three mice was pooled for each sample. RNA was extracted and purified from epidermis using solution D as described previously (Chomczynski and Sacchi, 1987) . RNA was DNase treated with 10 U DNase following manufacturer's instructions. DNase-treated RNA (2 mg) was reverse transcribed with M-MLV reverse transcriptase according to manufacturer's instructions and diluted to 100 ml with water. Real-time analysis was performed using primers and probes (FAM), which were either premade (TNFa) or designed using Primer Express 1.5a (TNFR1, TNFR2 and MMP-3). Multiplex real-time RT-PCR analysis was performed using the target primers and probes (FAM) and 18s rRNA primers and probes (VIC) with the ABI PRISM 7700 Sequence Detection System instrument and software. PCR was carried out with the TaqMan Universal PCR Master Mix using 2.5 ml of cDNA in a 25 ml final reaction mixture. Samples were incubated at 501C for 2 min followed by 10 min at 951C. The subsequent cycling conditions were 15 s at 951C and 1 min at 601C for a total of 40 cycles. Experiments were performed in triplicate for each sample. TNFR1, TNFR2, TNF-a or MMP-3 were normalized (DC t ) to 18s rRNA by subtracting the cycle threshold (C t ) value of 18s rRNA from the C t value of the gene of interest. 
Preparation of whole-cell epidermal homogenates
Mice were killed at the times indicated after four applications of TPA or acetone (control). Dorsally shaved treated skin was removed, spread on card and snap frozen in liquid nitrogen. Epidermis was subsequently scraped from dermis using a surgical scalpel and placed in ice-cold cell lysis buffer (1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate and 0.1% (w/v) SDS in PBS). Epidermis from three mice was pooled for each sample. Samples were homogenized using an Ultra-Turrax T25 homogenizer and incubated on ice for 10 min. Undigested tissue was removed by centrifugation at 15 000 g for 10 min.
The supernatant was collected and total protein concentration was determined using the BCA protein assay kit according to manufacturer's instructions.
ELISA for cytokines
Levels of TNFR1, TNFR2, TNF-a and GM-CSF protein were measured in whole-cell epidermal homogenates and NBK whole-cell extracts by ELISA at 1 mg/ml total protein for GM-CSF, TNFR1 and TNFR2 and 3 mg/ml for TNF-a according to manufacturer's instructions. GM-CSF was also measured in cell culture supernatant by ELISA. The TNFR1, TNFR2 and TNF-a levels detected in epidermal homogenates were representative of the soluble and transmembrane cellular pools of these proteins.
Preparation of cytosolic and nuclear epidermal homogenates
Mice were killed at the times indicated after one application of TPA or acetone (control). Cytosolic and nuclear fractions were prepared as described by Andrews and Faller (1991) . Briefly, epidermis was scraped from the dermis using a surgical scalpel. Epidermis from three mice was pooled for each sample. Samples were homogenized in ice-cold cytosolic lysis buffer (10 mM HEPES-KOH (pH 7.9; 41C), 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 0.5 mM dithiothreitol (DTT), 1 mM b-glycerophosphate, 1 mM sodium orthovanadate, 25 mg/ml aprotinin, 50 mg/ml leupeptin, 25 mg/ml pepstatin A, 1 mM phenylmethylsulfonylfluoride (PMSF)) using an Ultra-Turrax T8 homogenizer. Homogenates were centrifuged (30 000 g; 15 min; 41C) and the supernatant (cytosolic fraction) stored at À701C. The pellet was resuspended in ice-cold nuclear lysis buffer (20 mM HEPES-KOH (pH 7.9; 41C), 25% (v/v) glycerol, 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 0.5 mM DTT, 1 mM b-glycerophosphate, 1 mM sodium orthovanadate, 25 mg/ml aprotinin, 50 mg/ml leupeptin, 25 mg/ml pepstatin A, 1 mM PMSF) and incubated on ice for 20 min for high-salt extraction. Cellular debris was removed by centrifugation (30 000 g; 15 min; 41C) and the supernatant (nuclear fraction) stored at À701C. For cytosolic and nuclear extracts the Bio-Rad protein assay, based on the method of Bradford (1976) , was used.
SDS-PAGE and western blotting
Normalized epidermal homogenates were prepared by boiling with one-quarter volume of 5 Â concentrated Laemmli sample buffer (1001C, 5 min). Proteins were resolved on a 10% denaturing gel using 1 Â running buffer (25 mM Tris; 192 mM glycine, 0.1% (w/v) SDS). Sea-blue markers were used to determine protein size. Protein was transferred to nitrocellulose. Blots were blocked and antibody incubations performed according to the manufacturer's protocol. Proteins were visualized using ECLt reagent. To determine the intensity of bands, western blots were scanned using an Epson scanner and appropriate software. The image generated was then quantified using NIH image 1.61 software.
Zymography for MMP-9
MMP-9 protein in whole-cell epidermal homogenates or cell culture supernatant was measured by zymography as described previously (Leber and Balkwill, 1997) . To visualize the proform of MMP-9, 25 mg total protein or 25 ml of cell culture supernatant was loaded into each well with nonreducing sample buffer. Protein identity was confirmed using a pro-MMP-9 standard.
Isolation and culture of primary murine keratinocytes
Newborn keratinocytes (NBK) were isolated from 2-to 4-dayold wt, TNFR1 À/À and TNFR2 À/À mice as described in Roper et al. (2001) . Briefly, mice were killed and the skin was removed. The skin was stretched out epidermis side up and incubated in 2.5% (w/v) trypsin in tris saline solution overnight at 41C. The following day, epidermis was separated from dermis and epidermal cells were isolated by disaggregation. The cell suspension was passed through a 70 mM cell strainer and then centrifuged at 250 g for 10 min. Viable cells were counted using trypan blue exclusion and plated at 1.25 Â 10 7 cells per collagen I coated 10 cm dish. Cells were cultured for 7-10 days in FAD medium with 0.01 mM calcium containing 10% FBS (chelex treated to remove Ca 2 þ ) and HICE (0.5 mg/ml hydrocortisone, 5 mg/ml insulin, 0.1 nM cholera toxin and 10 ng/ml EGF). For experiments NBK were trypsinized and plated at 1 Â 10 6 cells/well in six-well plates. NBK were treated with increasing concentrations of recombinant murine TNF-a in FAD containing 4% FBS and HICE. Cell culture supernatant was collected 24 h after TNF-a treatment. MMP-9 and GM-CSF protein levels were measured in cell culture supernatant by zymography and ELISA, respectively. Whole-cell extracts were prepared for analysis of membrane bound TNFR1 and TNFR2 by ELISA. Briefly, adherent cells were scraped into ice-cold cell lysis buffer (1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate and 0.1% (w/v) SDS in PBS). Samples were homogenized using a 25 g needle, then centrifuged at 15 000 g for 10 min. The supernatant was collected and total protein concentration was determined using the BCA protein assay kit according to manufacturer's instructions.
Statistical analysis
The area under the curve (AUC) method was used to compare the total papilloma incidence in wt, TNFR1 À/À and TNFR2 À/À mice over the duration of each study. All statistical comparisons were made using the nonparametric Mann-Whitney U-test.
